Highlights
- •Cardiac sarcoidosis (CS) is a rare but fatal inflammatory disease.
- •Methotrexate is an effective steroid-sparing agent appropriate for the long-term treatment of CS.
- •Patients who do not respond or cannot tolerate corticosteroids or methotrexate are treated with infliximab.
- •Adalimumab is tumor necrosis factor alfa inhibitor that is safe in heart failure patients.
Abstract
Sarcoidosis is a disease of unknown etiology that continues to challenge clinicians
in its diagnosis and treatment. Although uncommon, cardiac involvement is fatal and
is the second most prevalent cause of death in sarcoidosis patients globally. This
article outlines the pathophysiology, diagnosis, and management of cardiac sarcoidosis
to guide nurse practitioners.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal for Nurse PractitionersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cardiac sarcoidosis.J Am Coll Cardiol. 2016; 68: 411-421https://doi.org/10.1016/j.jacc.2016.03.605
- Cardiac sarcoidosis: pathophysiology, diagnosis, and management.Hearts. 2021; 2: 234-250https://doi.org/10.3390/hearts2020019
- Cardiac sarcoidosis.Am J Cardiol. 2019; 123: 513-522https://doi.org/10.1016/j.amjcard.2018.10.021
- Trends in sarcoidosis mortality rate in Japan from 2001 to 2020: A population-based study.Respir Med. 2022; 196106828https://doi.org/10.1016/J.RMED.2022.106828
- Cardiac sarcoidosis: diagnosis and management.Rev Cardiovasc Med. 2020; 21: 321-338https://doi.org/10.31083/j.rcm.2020.03.102
- Sarcoid heart disease: an update on diagnosis and management.Curr Cardiol Rep. 2020; 22: 1-13https://doi.org/10.1007/s11886-020-01429-4
- A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis.J Am Acad Dermatol. 2013; 68: 765-773https://doi.org/10.1016/J.JAAD.2012.10.056
- Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.Chest. 2008; 133: 1189-1195https://doi.org/10.1378/CHEST.07-2952
- Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.Eur Respir J. 2008; 31: 1189-1196https://doi.org/10.1183/09031936.00051907
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Mol Med. 2012; 18: 1430-1436https://doi.org/10.2119/MOLMED.2012.00332
- Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT).Am Heart J. 2020; 220: 246-252https://doi.org/10.1016/j.ahj.2019.10.003
- Interleukin-1 blockade in cardiac sarcoidosis: study design of the Multimodality Assessment of Granulomas in Cardiac Sarcoidosis: Anakinra Randomized Trial (MAGiC-ART).J Transl Med. 2021; 19: 1-11https://doi.org/10.1186/s12967-021-03130-8
- Utility of updated Japanese Circulation Society guidelines to diagnose isolated cardiac sarcoidosis.J Am Heart Assoc. 2022; 1125565https://doi.org/10.1161/JAHA.122.025565
- JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis—digest version.Circ J. 2019; 83: 2329-2388https://doi.org/10.1253/circj.CJ-19-0508
- Diagnosis and detection of sarcoidosis an official American Thoracic Society Clinical Practice Guideline.Am J Respir Crit Care Med. 2020; 201: e26-e51https://doi.org/10.1164/rccm.202002-0251ST
- Cardiac magnetic resonance imaging-indeterminate/negative cardiac sarcoidosis revealed by 18 F-fluorodeoxyglucose-positron emission tomography: two case reports and a review of the literature.J Med Case Rep. 2017; 11https://doi.org/10.1186/s13256-017-1453-6
- Updates on the role of imaging in cardiac sarcoidosis.Curr Treat Options Cardiovasc Med. 2018; 20: 1-26https://doi.org/10.1007/s11936-018-0670-7
- New guidelines for diagnosis of cardiac sarcoidosis in Japan.Ann Nucl Cardiol. 2017; 3: 42-45https://doi.org/10.17996/anc.17-00042
- Cardiac sarcoidosis.Curr Cardiol Rep. 2019; 21: 1-10https://doi.org/10.1007/s11886-019-1238-1
- HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.Heart Rhythm. 2014; 11: 1304-1323https://doi.org/10.1016/j.hrthm.2014.03.043
- The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review.Eur Respir Rev. 2020; 29https://doi.org/10.1183/16000617.0057-2019
- Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies.Eur Respir J. 2022; 59https://doi.org/10.1183/13993003.00449-2021
- Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.Am J Cardiol. 2001; 88: 1006-1010https://doi.org/10.1016/S0002-9149(01)01978-6
- Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis.Am J Cardiol. 2016; 117: 966-971https://doi.org/10.1016/J.AMJCARD.2015.12.033
- State-of-the-art treatments for sarcoidosis.Methodist Debakey Cardiovasc J. 2022; 18: 94https://doi.org/10.14797/mdcvj.1068
- Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.Intern Med. 2014; 53: 427-433https://doi.org/10.2169/INTERNALMEDICINE.53.0794
- Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis.J Am Heart Assoc. 2019; 8https://doi.org/10.1161/JAHA.118.010952
- Low-dose methotrexate toxicity.CMAJ. 2019; 191: E423https://doi.org/10.1503/CMAJ.181054/-/DC1
- Infliximab for refractory cardiac sarcoidosis.Am J Cardiol. 2019; 124: 1630-1635https://doi.org/10.1016/j.amjcard.2019.07.067
- The many faces of cardiac sarcoidosis.Am J Clin Pathol. 2020; 153: 294-302https://doi.org/10.1093/ajcp/aqz169
- Arrhythmias associated with inflammatory cardiomyopathies.Curr Treat Options Cardiovasc Med. 2020; 22: 1-15https://doi.org/10.1007/s11936-020-00871-5
- Corticosteroid therapy for cardiac sarcoidosis: a systematic review.Can J Cardiol. 2013; 29: 1034-1041https://doi.org/10.1016/j.cjca.2013.02.004
- 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Circulation. 2018; 138: e272-e391https://doi.org/10.1161/CIR.0000000000000549
- Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis.Circ Arrhythm Electrophysiol. 2016; 9https://doi.org/10.1161/CIRCEP.115.003353
- Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis.Circ Arrhythm Electrophysiol. 2014; 7: 407-413https://doi.org/10.1161/CIRCEP.113.000734
- Renal manifestations of sarcoidosis: from accurate diagnosis to specific treatment.Int Braz J Urol. 2019; 46: 15-25https://doi.org/10.1590/S1677-5538.IBJU.2019.0042
Biography
Mohamed Toufic El Hussein, PhD, NP, is a professor at the School of Nursing and Midwifery, Faculty of Health, Community & Education Mount Royal University and Acute Care Nurse Practitioner Medical Cardiology, Coronary Care Unit, Rockyview General Hospital, Calgary, Alberta, Canada, and can be contacted at [email protected]
Biography
Nada Al-Wadeiah is a third-year nursing student at Mount Royal University, Calgary, Alberta, CA.
Biography
Nancy Clark, MN, NP, is the NP Manager - Cardiac Sciences and acute care nurse practitioner, medical cardiology, Coronary Care Unit, Rockyview General Hospital, Calgary, Alberta, CA.
Article info
Publication history
Published online: February 02, 2023
Footnotes
In compliance with standard ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
